DNLI: AVLAYAH’s launch accelerated as a broad pipeline approaches major 2027 readouts
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
AVLAYAH’s Q3 revenue reached $17.8M, driven by expanding coverage and faster patient transitions; Q4 guidance is $30M–$32M. A broad 2027 pipeline readout slate is ahead, supported by approximately $1.01B in cash and securities.Based on Denali Therapeutics Inc. [DNLI] Q3 2026
Directly affected
- DNLI Denali Therapeutics-2.0% 15d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Denali Therapeutics belongs to, so it often moves with news about it.
- AMGN Amgen+15.9% 30d
Amgen is a peer of Denali Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+16.4% 30d
Gilead Sciences is a peer of Denali Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+22.4% 30d
Moderna is a peer of Denali Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- ARGX argenx SE-11.9% 9d
argenx SE is a peer of Denali Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of Denali Therapeutics in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| DNLI | -1.03% | -2.82% | base | +7.44% | +1.18% | +2.90% | +4.44% |
| XLV | -2.31% | +0.48% | base | +3.08% | +0.53% | +0.43% | +2.39% |
| AMGN | -2.03% | +1.07% | base | +3.67% | -0.14% | -0.19% | +0.88% |
| GILD | -4.93% | +2.07% | base | +4.16% | +0.01% | -0.37% | +1.13% |
| MRNA | -6.29% | -2.97% | base | +13.13% | +5.69% | +11.43% | +17.78% |
| ARGX | -1.09% | -0.93% | base | +3.36% | -0.78% | +3.07% | +6.90% |
| RVMD | -2.84% | -1.45% | base | +2.75% | -8.41% | -0.96% | +3.13% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
DNLI: AVLAYAH’s launch accelerated as a broad pipeline approaches major 2027 readouts TradingView
Source: TradingView
Energy
| Company | When | Move | Status |
|---|---|---|---|
| AMGN | that day | +3.67% | final price |
| AMGN | the next day | -0.14% | final price |
| AMGN | two days later | -0.19% | final price |
| AMGN | three days later | +0.88% | final price |
| AMGN | three days earlier | +1.07% | final price |
| AMGN | five days earlier | -2.03% | final price |
| ARGX | that day | +3.36% | final price |
| ARGX | the next day | -0.78% | final price |
| ARGX | two days later | +3.07% | final price |
| ARGX | three days later | +6.90% | final price |
| ARGX | three days earlier | -0.93% | final price |
| ARGX | five days earlier | -1.09% | final price |
| DNLI | that day | +7.44% | final price |
| DNLI | the next day | +1.18% | final price |
| DNLI | two days later | +2.90% | final price |
| DNLI | three days later | +4.44% | final price |
| DNLI | three days earlier | -2.82% | final price |
| DNLI | five days earlier | -1.03% | final price |
| GILD | that day | +4.16% | final price |
| GILD | the next day | +0.01% | final price |
| GILD | two days later | -0.37% | final price |
| GILD | three days later | +1.13% | final price |
| GILD | three days earlier | +2.07% | final price |
| GILD | five days earlier | -4.93% | final price |
| MRNA | that day | +13.13% | final price |
| MRNA | the next day | +5.69% | final price |
| MRNA | two days later | +11.43% | final price |
| MRNA | three days later | +17.78% | final price |
| MRNA | three days earlier | -2.97% | final price |
| MRNA | five days earlier | -6.29% | final price |
| RVMD | that day | +2.75% | final price |
| RVMD | the next day | -8.41% | final price |
| RVMD | two days later | -0.96% | final price |
| RVMD | three days later | +3.13% | final price |
| RVMD | three days earlier | -1.45% | final price |
| RVMD | five days earlier | -2.84% | final price |
| XLV | that day | +3.08% | final price |
| XLV | the next day | +0.53% | final price |
| XLV | two days later | +0.43% | final price |
| XLV | three days later | +2.39% | final price |
| XLV | three days earlier | +0.48% | final price |
| XLV | five days earlier | -2.31% | final price |
Congressional trades in the stocks in this story
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $15,001 - $50,000 on 15 Oct 2026. That is 20 days before publication. Filed 2 Nov 2026. View the filing.
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 43 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 70 days before publication. Filed 5 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 86 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Gilbert Cisneros bought Moderna (MRNA), worth $1,001 - $15,000 on 20 Oct 2026. That is 15 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $1,001 - $15,000 on 27 Oct 2026. That is 8 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $1,001 - $15,000 on 15 Oct 2026. That is 20 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Argenx Se (ARGX), worth $15,001 - $50,000 on 14 Oct 2026. That is 21 days before publication. Filed 10 Nov 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid the energy case looks
12 out of 100
“DNLI: AVLAYAH’s launch accelerated as a broad pipeline approaches major 2027 readouts” scores 12 out of 100. The score uses 1 sources.